Founded: 2002
Arcadia Biosciences reports Q4 results
- Q4 net loss $3 mln vs. 5.7 mln last year; rev +165% to $1.43 mln. Co in-licensed CRISPR-Cas9 gene editing technology and began integrating the technology to accelerate current development programs.
- In 2018, Arcadia will launch its commercialization plan to become a consumer-driven, branded food ingredient company providing value-added traits to the health and nutrition foods industries.
- Arcadia hired Sarah Reiter as chief commercial officer, with over 20 years of experience in agriculture, to help us migrate forward in the ag-food supply chain, expand our nutrition and health ingredients capabilities and strengthen commercial relationships with consumer food companies.
No comments:
Post a Comment